A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
← catalyst calendarSponsored by Agenus Inc. (industry) · AGEN — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
81actual
Sites
36
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-27 | actual | When the study began enrolling |
| Primary completion | 2026-01-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-05 | actual | The whole study's end, after follow-up |
| First posted | 2022-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: Botensilimab — also filed as AGEN1181
- Drug: Gemcitabine
- Drug: Nab-paclitaxel
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival as Assessed by Investigator
measured Up to 2 years
Permalink · AGEN's whole pipeline · Catalyst calendar · Every registered study · What changed